An accurate and selective high-performance liquid chromatography with
ultraviolet detector (HPLC-UV) method was developed for quantification of alibendol
in human plasma. The sample was prepared by one-step liquid-liquid extraction (LLE)
using ethyl acetate from plasma. The chromatographic retention times of alibendol and carvedilol (the internal standard;
IS) were 4.3 and 3.5 min, respectively, on a reverse phase C18 CAPCELL PAK (250 mm 4.6 mm I.D., 5 μm) column.
The isocratic mobile phase consisted of acetonitrile-10 mM sodium phosphate (45:55, v/v; adjusted to pH 3.0 with phosphoric
acid). The lower limit of quantitation (LLOQ) was 0.3 μg/mL and no interferences were detected in chromatograms.
The developed HPLC method was validated by evaluating its inter- and intra-day precisions and accuracies for a
linear concentration range of 0.3 and 20.0 μg/mL. Stability testing showed that alibendol was stable in human plasma during
sample processing and storage. The proposed method was successfully applied to the pharmacokinetic study of the
single-dose oral administration of 100 mg alibendol tablet in healthy Korean male volunteers. The Cmax, T1/2 and AUC0-t
of alibendol were 5.82 ± 1.40 μg/mL, 1.47 ± 0.43 h, 10.62 ± 2.40 μg·h/mL, respectively.
Keywords: Alibendol, HPLC-UV, liquid-liquid extraction, human plasma, pharmacokinetic study.
Rights & PermissionsPrintExport